We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.58%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.89B
AUM Growth
+$619M
Cap. Flow
+$427M
Cap. Flow %
14.76%
Top 10 Hldgs %
55.7%
Holding
79
New
14
Increased
13
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$117M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$83.5M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$52.2M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.2M
5
RLAY icon
Relay Therapeutics
RLAY
+$47.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$107M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$36.3M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$33M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$6.45M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 85.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$30.8M 1.07%
2,400,000
– –
BCEL
27
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$30.8M 1.06%
2,202,333
+468,750
+27% +$6.99M
AMRN
28
Amarin Corp
AMRN
$299M
$29.5M 1.02%
350,000
– –
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$29M 1%
4,000,000
+2,000,000
+100% +$10.7M
QURE icon
30
uniQure
QURE
$3.03B
$28.2M 0.97%
765,400
– –
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.42B
$27.7M 0.96%
2,202,812
– –
AKRO
32
DELISTED
Akero Therapeutics
AKRO
$25.6M 0.88%
831,495
+415,000
+100% +$14.5M
PASG icon
33
Passage Bio
PASG
$14.4M
$25.3M 0.87%
96,416
– –
KDMN
34
DELISTED
Kadmon Holdings, Inc.
KDMN
$24.3M 0.84%
6,205,882
– –
PAND
35
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$24.2M 0.83%
+2,107,513
New +$36M
PNT
36
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$21.6M 0.75%
+1,500,000
New +$20.5M
ANAB icon
37
AnaptysBio
ANAB
$1.58B
$19.2M 0.66%
1,300,000
– –
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$11.6B
$19M 0.66%
250,000
– –
NGNE icon
39
Neurogene
NGNE
$656M
$18M 0.62%
75,053
+24,590
+49% +$5.96M
CABA icon
40
Cabaletta Bio
CABA
$437M
$17M 0.59%
1,566,361
– –
KOD icon
41
Kodiak Sciences
KOD
$2.6B
$16.3M 0.56%
275,138
+94,000
+52% +$4.72M
AGEN
42
Agenus
AGEN
$312M
$16M 0.55%
203,800
– –
ACAD icon
43
Acadia Pharmaceuticals
ACAD
$4.43B
$15.3M 0.53%
370,000
– –
LABD icon
44
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$14.9M 0.52%
25,000
-10,000
-29% -$6.45M
CLDX icon
45
Celldex Therapeutics
CLDX
$2.99B
$14.8M 0.51%
1,000,000
– –
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.8M 0.48%
250,000
– –
SPPI
47
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$13.6M 0.47%
+3,333,333
New +$12.7M
DBVT
48
DBV Technologies
DBVT
$799M
$13M 0.45%
753,460
+50,000
+7% +$1.44M
MIST icon
49
Milestone Pharmaceuticals
MIST
$138M
$13M 0.45%
1,777,194
+675,000
+61% +$4.84M
PRVL
50
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$11.4M 0.4%
1,123,105
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Boxer Capital held 79 positions worth $2.89B, up 27% from $2.27B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital deployed $427M of net new capital in Q3 2020, opening 14 new positions and adding to 13 existing holdings. Its largest new stake was iTeos Therapeutics: 4,345,016 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $107M trimmed.

  • Boxer Capital's largest Q3 2020 buy was iTeos Therapeutics: 4,345,016 shares worth $107M.
  • Boxer Capital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $52.2M increase.
  • Boxer Capital's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $107M.
  • Boxer Capital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $36.3M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.89B portfolio in Q3 2020.
  • Boxer Capital opened 14 new positions and closed 4 in Q3 2020.
  • Boxer Capital's portfolio value rose 27% quarter-over-quarter to $2.89B.

Based on Boxer Capital's 13F filing for Q3 2020, filed 16 Nov 2020.